MedTrace Logo

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

NCT02468193 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-05-06

Study results available
· View outcomes & findings →

Summary

The study aim was to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.

Conditions

  • Cushing's Syndrome
  • Ectopic Corticotropin Syndrome
  • Adrenal Adenoma
  • Adrenal Carcinoma
  • AIMAH
  • PPNAD

Interventions

DRUG

Osilodrostat

Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-24
Primary Completion
2018-06-07
Completion
2018-10-29

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02468193 on ClinicalTrials.gov